Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Amgen has a lot riding on an experimental obesity drug that it hopes will rival those of Eli Lilly and Novo Nordisk. But one ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Find out more about five biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.